Open Access
Issue
E3S Web Conf.
Volume 245, 2021
2021 5th International Conference on Advances in Energy, Environment and Chemical Science (AEECS 2021)
Article Number 03053
Number of page(s) 4
Section Chemical Performance Research and Chemical Industry Technology Research and Development
DOI https://doi.org/10.1051/e3sconf/202124503053
Published online 24 March 2021
  1. Addy, D.P., Cystic fibrosis: current survival and population estimates to the year 2000. Thorax, 1992. 47(4): p. 327. [Google Scholar]
  2. Burgel, P.-R., et al., Future trends in cystic fibrosis demography in 34 European countries. European Respiratory Journal, 2015. 46(1): p. 133. [Google Scholar]
  3. Davis, P.B., Another Beginning for Cystic Fibrosis Therapy. New England Journal of Medicine, 2015. 373(3): p. 274–276. [Google Scholar]
  4. Parkins, M.D., et al., Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. Therapeutic Advances in Respiratory Disease, 2010. 5(2): p. 105–119. [PubMed] [Google Scholar]
  5. Stoltz, D.A., D.K. Meyerholz, and M.J. Welsh, Origins of Cystic Fibrosis Lung Disease. New England Journal of Medicine, 2015. 372(4): p. 351–362. [Google Scholar]
  6. Henderson, A.G., et al., Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. The Journal of Clinical Investigation, 2014. 124(7): p. 3047–3060. [CrossRef] [PubMed] [Google Scholar]
  7. Button, B., et al., A Periciliary Brush Promotes the Lung Health by Separating the Mucus Layer from Airway Epithelia. Science, 2012. 337(6097): p. 937. [Google Scholar]
  8. Boucher, R.C., Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2010. 181(10): p. 1017–1019. [PubMed] [Google Scholar]
  9. Ratjen, F.A., Cystic Fibrosis: Pathogenesis and Future Treatment Strategies. Respiratory Care, 2009. 54(5): p. 595. [CrossRef] [PubMed] [Google Scholar]
  10. Castellani, C., et al., Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Journal of Cystic Fibrosis, 2008. 7(3): p. 179–196. [Google Scholar]
  11. Elborn, J.S., Cystic fibrosis. The Lancet, 2016. 388(10059): p. 2519–2531. [Google Scholar]
  12. Kelly, T. and J. Buxbaum, Gastrointestinal Manifestations of Cystic Fibrosis. Digestive Diseases and Sciences, 2015. 60(7): p. 1903–1913. [PubMed] [Google Scholar]
  13. Corrigendum. Therapeutic Advances in Chronic Disease, 2016. 7(3): p. 184–184. [PubMed] [Google Scholar]
  14. Richard, B.M., Cystic Fibrosis: Pathogenesis, Pulmonary Infection, and Treatment. Clinical Infectious Diseases, 1995. 21(4): p. 839–849. [Google Scholar]
  15. Yu, H., et al., Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of Cystic Fibrosis, 2012. 11(3): p. 237–245. [Google Scholar]
  16. McKone, E.F., et al., Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). The Lancet Respiratory Medicine, 2014. 2(11): p. 902–910. [PubMed] [Google Scholar]
  17. Van Goor, F., et al., Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proceedings of the National Academy of Sciences, 2011. 108(46): p. 18843. [Google Scholar]
  18. Bear, C.E., A Therapy for Most with Cystic Fibrosis. Cell, 2020. 180(2): p. 211. [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.